# Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

> **NCT06934057** · PHASE4 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 50 (estimated)

## Conditions studied

- Kidney Cancer
- Renal Cell Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT06934057
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934057, "Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06934057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*